Drug - Crixivan
The trade name of the product as shown on the labeling.

The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Indinavir Sulfate
Multiple ingredients are in alphabetical order.

Strength - EQ 200MG BASE
The potency of the active ingredient(s), Indinavir Sulfate. May repeat for multiple part products.

Applicant - MERCK
The firm name holding legal responsibility for Crixivan. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020685
The FDA assigned number to Crixivan. Format is nnnnnn.

Product Number - 003
The FDA assigned number to identify Crixivan. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Mar 13, 1996
The date Crixivan was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Crixivan. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Crixivan is in. Format is RX, OTC, DISCN.

Applicant Full Name - Merck Research Laboratories Div Merck Co Inc
The full name of the firm holding legal responsibility for the new application of Crixivan.